This preprint is under consideration at BMC Pulmonary Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Eiji Nakatani
Shizuoka General Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing non-invasive pneumococcal pneumonia (non-IPD) has been controversial.
Methods: To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case-control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department.
Results: There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95 % confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95 % CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12).
Conclusion: This real-world study suggests that PPSV23 is effective in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases and in the older population (age ≥ 75 years).
Keywords
chronic respiratory disease, elderly, pneumococcal polysaccharide vaccine, pneumococcus, pneumonia, vaccine
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 18 Mar, 2021
Review #3 received
Received 14 Mar, 2021
Review #4 received
Received 14 Mar, 2021
Review #5 received
Received 14 Mar, 2021
Review #2 received
Received 14 Mar, 2021
Review #1 received
Received 14 Mar, 2021
Reviewer #1 agreed
On 08 Mar, 2021
Reviewer #5 agreed
On 08 Mar, 2021
Reviewer #6 agreed
On 08 Mar, 2021
Reviewer #7 agreed
On 08 Mar, 2021
Reviewer #4 agreed
On 08 Mar, 2021
Reviewer #3 agreed
On 08 Mar, 2021
Reviewer #2 agreed
On 08 Mar, 2021
Reviewers invited
Invitations sent on 08 Mar, 2021
Editor assigned
On 03 Mar, 2021
Editor invited
On 03 Mar, 2021
Submission checks complete
On 03 Mar, 2021
First submitted
On 28 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pulmonology
Learn more about our company.
This preprint is under consideration at BMC Pulmonary Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Eiji Nakatani
Shizuoka General Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 18 Mar, 2021
Review #3 received
Received 14 Mar, 2021
Review #4 received
Received 14 Mar, 2021
Review #5 received
Received 14 Mar, 2021
Review #2 received
Received 14 Mar, 2021
Review #1 received
Received 14 Mar, 2021
Reviewer #1 agreed
On 08 Mar, 2021
Reviewer #5 agreed
On 08 Mar, 2021
Reviewer #6 agreed
On 08 Mar, 2021
Reviewer #7 agreed
On 08 Mar, 2021
Reviewer #4 agreed
On 08 Mar, 2021
Reviewer #3 agreed
On 08 Mar, 2021
Reviewer #2 agreed
On 08 Mar, 2021
Reviewers invited
Invitations sent on 08 Mar, 2021
Editor assigned
On 03 Mar, 2021
Editor invited
On 03 Mar, 2021
Submission checks complete
On 03 Mar, 2021
First submitted
On 28 Feb, 2021
Subject Areas
Pulmonology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing non-invasive pneumococcal pneumonia (non-IPD) has been controversial.
Methods: To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case-control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department.
Results: There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95 % confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95 % CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12).
Conclusion: This real-world study suggests that PPSV23 is effective in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases and in the older population (age ≥ 75 years).
Figure 1
Figure 2
Loading...